In December 2016 Sumitomo Dainippon Pharma Co. Ltd. anounced acquisition of privately held oncology firm Tolero Pharmaceuticals Inc. for cash up front, significant earn-outs based on development achievements and payment based on net sales. Tolero Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops novel therapeutics to treat and cure cancer and other life-threatening diseases in the United States. Its products include TP-0413 that targets a signaling pathway complicated in the regulation of serum iron levels for individuals suffering with chronic inflammatory diseases, such as cancer and rheumatoid arthritis; TP-0829, which targets a vital component of the B-cell receptor signaling pathway for the treatment of B-cell lymphomas, B-cell leukemia, and multiple myeloma; and TP-0903, a dual-targeted agent that inhibits two signaling pathways for pancreatic cancer cell growth and survival, and for the maintenance of the tumor stromal cells. The companyâs products also comprise TP-0227 that targets a signaling pathway deregulated in cancer cells particularly in endometrial carcinomas; and TP-1149 that targets a cellular mechanism to render myeloma cells resistant to current therapeutic approaches. Tolero Pharmaceuticals, Inc. has strategic partnerships with MannKind Corporation and Eutropics, Inc.
